Movement Alert｜GenScript Biotech Falls 6.34% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Triggers Profit-Taking

Market Focus07-16 09:43

On July 16, GenScript Biotech fell 6.34% in regular trading, trading at HK$14.1/share, with turnover of HK$57.82 million.

On the news front, the company disclosed after the previous session that its associate Legend Biotech reported CARVYKTI Q2 net trade sales of approximately US$657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's US$597 million. The quarter-over-quarter growth rate decelerated notably compared to the 62% year-over-year surge recorded in Q1. Market participants interpreted the slowdown as a signal of moderating commercial momentum.

GenScript had rallied over 5% on each of July 13 and July 15, driven by optimism around CXO sector mid-year earnings expectations, accumulating significant gains. Following the release of the Q2 sales figure — which some market commentary suggested fell short of consensus expectations — profit-taking pressure intensified, reversing the prior rally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141797138?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141797138","market":"us","top_or_hot":-1,"title":"Movement Alert｜GenScript Biotech Falls 6.34% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Triggers Profit-Taking","media":"Market Focus","content":"<p><p>On July 16, GenScript Biotech fell 6.34% in regular trading, trading at HK$14.1/share, with turnover of HK$57.82 million.</p><p>On the news front, the company disclosed after the previous session that its associate Legend Biotech reported CARVYKTI Q2 net trade sales of approximately US$657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's US$597 million. The quarter-over-quarter growth rate decelerated notably compared to the 62% year-over-year surge recorded in Q1. Market participants interpreted the slowdown as a signal of moderating commercial momentum.</p><p>GenScript had rallied over 5% on each of July 13 and July 15, driven by optimism around CXO sector mid-year earnings expectations, accumulating significant gains. Following the release of the Q2 sales figure — which some market commentary suggested fell short of consensus expectations — profit-taking pressure intensified, reversing the prior rally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GenScript Biotech Falls 6.34% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Triggers Profit-Taking</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GenScript Biotech Falls 6.34% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Triggers Profit-Taking\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, GenScript Biotech fell 6.34% in regular trading, trading at HK$14.1/share, with turnover of HK$57.82 million.</p><p>On the news front, the company disclosed after the previous session that its associate Legend Biotech reported CARVYKTI Q2 net trade sales of approximately US$657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's US$597 million. The quarter-over-quarter growth rate decelerated notably compared to the 62% year-over-year surge recorded in Q1. Market participants interpreted the slowdown as a signal of moderating commercial momentum.</p><p>GenScript had rallied over 5% on each of July 13 and July 15, driven by optimism around CXO sector mid-year earnings expectations, accumulating significant gains. Following the release of the Q2 sales figure — which some market commentary suggested fell short of consensus expectations — profit-taking pressure intensified, reversing the prior rally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1141797138","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141797138","pubTimestamp":1784166231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, GenScript Biotech fell 6.34% in regular trading, trading at HK$14.1/share, with turnover of HK$57.82 million.On the news front, the company disclosed after the previous session that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易下跌6.34%，CARVYKTI Q2销售增长放缓引发获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On July 16, GenScript Biotech fell 6.34% in regular trading, trading at HK$14.1/share, with turnover of HK$57.82 million.On the news front, the company disclosed after the previous session that its associate Legend Biotech reported CARVYKTI Q2 net trade sales of approximately US$657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's US$597 million. The quarter-over-quarter growth rate decelerated notably compared to the 62% year-over-year surge recorded in Q1. Market participants interpreted the slowdown as a signal of moderating commercial momentum.GenScript had rallied over 5% on each of July 13 and July 15, driven by optimism around CXO sector mid-year earnings expectations, accumulating significant gains. Following the release of the Q2 sales figure — which some market commentary suggested fell short of consensus expectations — profit-taking pressure intensified, reversing the prior rally.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141797138","isCrawlerRequest":true}